Sign In Join Help
 
JinanJianfengChemicalCo.,Ltd.

 
 
Recommended Results 
 
Apixaban intermeidate Cas 545445-44-1 

  Category : Chemicals->active pharmaceutical ingredient

     
Apixaban intermeidate Cas 545445-44-1
       

  Product Specification
 
  Country  CN

 

    Product Detail
  <p class="MsoNormal">
Chemical&nbsp;Name: 3-Morpholino-1-(4-(2-oxopiperidin-1-yl)phenyl)-5,6-dihydropyridin-2(1H)-one
</p>
<p class="MsoNormal">
Molecular&nbsp;Formula: C20H25N3O3<br />
Formula&nbsp;Weight: 355<br />
CAS&nbsp;No.: 545445-44-1
</p>
<p class="MsoNormal">
<img src="http://i.bosscdn.com/product/e0/26/d3/df60537fa57cd5a64a040e3808.gif" title="545445-44-1" alt="545445-44-1" /><br />
An&nbsp;alternate&nbsp;approach&nbsp;to&nbsp;apixaban&nbsp;was&nbsp;described.&nbsp;The&nbsp;synthesis&nbsp;features&nbsp;a&nbsp;novel&nbsp;and&nbsp;cost-effective&nbsp;synthetic&nbsp;strategy&nbsp;to&nbsp;construct&nbsp;a&nbsp;key&nbsp;N-phenylvalerolactam&nbsp;intermediate&nbsp;4&nbsp;from&nbsp;4-nitroaniline.&nbsp;In&nbsp;addition,&nbsp;the&nbsp;modifiedStroke Prophylaxis with Atrial Fibrillation<br />
Indicated to reduce risk of stroke and systemic embolism associated with nonvalvular atrial fibrillation<br />
<br />
5 mg PO BID<br />
<br />
Postoperative Prophylaxis of DVT/PE<br />
Indicated following hip or knee replacement surgery<br />
<br />
Initial: Give 2.5 mg PO 12-24 hr after surgery<br />
<br />
Duration of therapy (hip replacement): 2.5 mg PO BID for 35 days<br />
<br />
Duration of therapy (knee replacement): 2.5 mg PO BID for 12 days<br />
<br />
Renal impairment, including with ESRD on dialysis<br />
<br />
Deep Vein Thrombosis: No dose adjustment recommended; clinical efficacy and safety studies did not enroll patients with ESRD on dialysis or patients with a CrCl &lt;15 mL/min; dosing recommendations are based on pharmacokinetic and pharmacodynamic (anti-FXa activity) data in study subjects with ESRD maintained on dialysis<br />
&nbsp;synthetic&nbsp;route&nbsp;avoids&nbsp;the&nbsp;use&nbsp;of&nbsp;expensive&nbsp;reagents&nbsp;and&nbsp;significantly&nbsp;improves&nbsp;reaction&nbsp;yields.&nbsp;As&nbsp;demonstrated&nbsp;practically,&nbsp;apixaban&nbsp;was&nbsp;successfully&nbsp;synthesized&nbsp;in&nbsp;overall&nbsp;good&nbsp;yield&nbsp;(35%).
</p>
<p class="MsoNormal">
<br />
</p>pharmachemm.com

  More Products from this Supplier
 
Cas 330786-24-8 ibrutinib impurity

Cas 330786-24-8 ibrutinib impurity
Tadanafil intermediate cas 171489-59-1 Chloropretadalafil

Tadanafil intermediate cas 171489-59-1 Chloropretadalafil
Cas 160844-75-7 Febuxostat intermediate

Cas 160844-75-7 Febuxostat intermediate
Hydroxycholesterol cas 2140-46-7 Eldecalcitol ED-71

Hydroxycholesterol cas 2140-46-7 Eldecalcitol ED-71
 
   


[ Back Products Catalog ]

Commerce Member:
Please log in your ID and password, we will later fill in relating info.
 
ID: Password: Remember my ID on this computer
Complete this form below to send out your enquiries.
All enquiries will be automatically sent to the company you want to develop.
Subject
Content (Don't input Company Name, E-Mail, Phone Number, Fax Number, and URL)
   

 


Company Profile:
* Company Name
*E-mail
*Country
*Contact Person
URL
*Phone
 - -
Fax
 - -
*Postal code
*City
*Street Address
*Business Nature
 Distributor   Exporter Importer Manufacturer
Whole Sale Retailer  Reseller Retrofitter User
Others, please specify:
*Security Code
Enter the security code.


Site Map l   Privacy Policy l Company Profile l Corporate Proposal l Contact Us l Help l Advertise With Us l  World Trade Link
    .